1 week Ago By ABMN Staff
JPMorgan Chase & Co. boosted its holdings in Veracyte, Inc. ( NASDAQ:VCYT – Free Report ) by 25.
5% during the fourth quarter, Holdings Channel.com reports. The fund owned 434,971 shares of the biotechnology company’s stock after acquiring an additional 88,384 shares during the period.
JPMorgan Chase & Co.’s holdings in Veracyte were worth $17,225,000 at the end of the most recent reporting period. Several other hedge funds have also recently added to or reduced their stakes in VCYT.
Jones Financial Companies Lllp lifted its stake in Veracyte by 49.7% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 237 shares in the last quarter.
US Bancorp DE lifted its position in shares of Veracyte by 57.4% in the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 647 shares in the last quarter.
Principal Securities Inc. boosted its stake in shares of Veracyte by 34.1% during the fourth quarter.
Principal Securities Inc. now owns 1,909 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 485 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Veracyte during the 4th quarter worth about $91,000.
Finally, KBC Group NV raised its stake in Veracyte by 44.6% in the 4th quarter. KBC Group NV now owns 3,872 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 1,195 shares during the last quarter.
Veracyte Trading Up 5.1 % Shares of VCYT stock opened at $31.80 on Friday.
The company’s fifty day simple moving average is $34.26 and its 200-day simple moving average is $37.45.
Veracyte, Inc. has a 52 week low of $18.61 and a 52 week high of $47.
32. The company has a market cap of $2.48 billion, a PE ratio of -212.
00 and a beta of 2.03. Analysts Set New Price Targets A number of research firms have recently weighed in on VCYT.
StockNews.com lowered shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Guggenheim reduced their price target on Veracyte from $45.
00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group lifted their price objective on Veracyte from $46.
00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Needham & Company LLC reiterated a “buy” rating and issued a $51.
00 target price on shares of Veracyte in a research note on Tuesday, February 25th. Finally, Stephens reissued an “overweight” rating and issued a $45.00 price target on shares of Veracyte in a research note on Wednesday, March 26th.
One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Veracyte has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.
Check Out Our Latest Stock Analysis on VCYT About Veracyte ( Free Report ) Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis.
The company was founded by Bonnie H. Read More Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc.
( NASDAQ:VCYT – Free Report ). Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter .
.
